The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl
about
Autoantibodies directed to novel components of the PM/Scl complex, the human exosomeThe clinical relevance of autoantibodies in sclerodermaThe human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma.Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes.Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls.Laboratory evaluation of the inflammatory myopathies.Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma.Recent advances in the immunogenetics of idiopathic inflammatory myopathy.Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis.Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical featuresHLA markers for poor prognosis in systemic sclerosis Brazilian patients.Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.Bilateral coxitis in scleroderma-polymyositis overlap syndrome.The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis.Caspase-mediated cleavage of the exosome subunit PM/Scl-75 during apoptosis
P2860
Q24292404-1CC595F1-7855-4DEA-8849-4CC0EA5AA021Q24682842-97CA705E-BAA4-449B-9C15-79B989B2C4A8Q24805333-B743C0AB-27C1-40DA-B2AE-3AE1664D9FC6Q33293736-F8423BF3-F368-4D37-98CE-394530BD233FQ34046875-C95B026F-A402-4B08-852B-FE243E5FAB69Q35223951-05052A7D-4EF1-4670-901C-F27B018C85DCQ35532333-757C143E-AF3D-4983-936C-46C318EC0014Q35557800-06AD7272-4CA4-4AC0-A0D6-F949C31292A9Q35760198-750D8A12-1212-41FC-A47C-FD7DB6FC3BFBQ35840816-9D79087E-84B2-4DD2-8D0F-2529FFF011D5Q37176585-07719EE0-A61F-43A5-B789-BF55F2FAAEF4Q37207105-CB64F3D8-F3BC-4D6B-9127-D49268597E2BQ37296343-6705320E-AFDF-4C02-8A78-FEF5B293D7CEQ37427265-8B08DCBF-AF14-46ED-8702-5C7BA9CC6ED0Q40292542-1C2E200C-2A60-4619-8D13-BE965E679E47Q42213201-D2809A46-3558-4835-A2EB-1AA61617D827Q42836117-08818549-F7D8-4BFD-8D6D-121263EECB4A
P2860
The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl
description
im November 1992 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 November 1992
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 1992
@uk
name
The clinical and immunogenetic ...... o the nucleolar antigen PM-Scl
@en
The clinical and immunogenetic ...... o the nucleolar antigen PM-Scl
@nl
type
label
The clinical and immunogenetic ...... o the nucleolar antigen PM-Scl
@en
The clinical and immunogenetic ...... o the nucleolar antigen PM-Scl
@nl
prefLabel
The clinical and immunogenetic ...... o the nucleolar antigen PM-Scl
@en
The clinical and immunogenetic ...... o the nucleolar antigen PM-Scl
@nl
P2093
P1433
P1476
The clinical and immunogenetic ...... o the nucleolar antigen PM-Scl
@en
P2093
C Marguerie
J M Gilroy
R M Bernstein
P304
P356
10.1097/00005792-199211000-00001
P407
P50
P577
1992-11-01T00:00:00Z